Advertisement
Advertisement
U.S. Markets open in 6 hrs 32 mins
Advertisement
Advertisement
Advertisement
Advertisement

CytoDyn Inc. (CYDY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4400+0.0325 (+7.98%)
At close: 03:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4075
Open0.3900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3900 - 0.4470
52 Week Range0.2300 - 2.5400
Volume908,344
Avg. Volume2,354,224
Market Cap290.484M
Beta (5Y Monthly)-0.80
PE Ratio (TTM)N/A
EPS (TTM)-0.2550
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    CytoDyn to Hold Webcast to Provide a Quarterly Company Update

    VANCOUVER, Washington, June 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Director of Research & Developm

  • GlobeNewswire

    CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer

    VANCOUVER, Washington, May 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has reached a non-cash settlement with its former Chief Medical Officer, Dr. Richard Pestell, concerning an ongoing legal dispute related to his former employment with the Company. Under the terms of the agreement, the parties will release e

  • GlobeNewswire

    CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor

    VANCOUVER, Washington, May 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the addition of Dr. Paul Edison, Dr. Kabir Mody, and Dr. Otto Yang to the Company’s Scientific Board of Advisors. In addition, Dr. Jay Lalezari has agreed to serve as an outside Scientific Advisor to the Company. Dr. Paul Edison is a Senior Clinical

Advertisement
Advertisement